SI2099447T1 - Imidazotriazini in imidazopirimidini kot inhibitorji kinaz - Google Patents

Imidazotriazini in imidazopirimidini kot inhibitorji kinaz

Info

Publication number: SI2099447T1
Authority: SI; Slovenia
Prior art keywords: imidazotriazines; imidazopyrimidines; kinase inhibitors; kinase; inhibitors
Prior art date: 2006-11-22

Application number

SI200731149T

Other languages

English (en)

Inventor

Jincong Zhuo

Brian Metcalf

Meizhong Xu

Chunhong He

Colin Zhang

Ding-Quan Qian

David M. Burns

Yunlong Li

Wenqing Yao

Original Assignee

Incyte Corporation Experimental Station E336/205

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-22

Filing date

2007-11-19

Publication date

2013-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2099447(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-11-19 Application filed by Incyte Corporation Experimental Station E336/205 filed Critical Incyte Corporation Experimental Station E336/205

2013-03-29 Publication of SI2099447T1 publication Critical patent/SI2099447T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SI200731149T 2006-11-22 2007-11-19 Imidazotriazini in imidazopirimidini kot inhibitorji kinaz SI2099447T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US86084006P	2006-11-22	2006-11-22
US86145906P	2006-11-29	2006-11-29
US95723607P	2007-08-22	2007-08-22
EP07864592A EP2099447B1 (en)	2006-11-22	2007-11-19	Imidazotriazines and imidazopyrimidines as kinase inhibitors
PCT/US2007/085100 WO2008064157A1 (en)	2006-11-22	2007-11-19	Imidazotriazines and imidazopyrimidines as kinase inhibitors

Publications (1)

Publication Number	Publication Date
SI2099447T1 true SI2099447T1 (sl)	2013-03-29

Family

ID=39166437

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI200732055T SI3034075T1 (sl)	2006-11-22	2007-11-19	Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
SI200731739T SI2497470T1 (sl)	2006-11-22	2007-11-19	Imidazotriazini in imidazopirimidini kot inhibitorji kinaz
SI200731149T SI2099447T1 (sl)	2006-11-22	2007-11-19	Imidazotriazini in imidazopirimidini kot inhibitorji kinaz

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SI200732055T SI3034075T1 (sl)	2006-11-22	2007-11-19	Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
SI200731739T SI2497470T1 (sl)	2006-11-22	2007-11-19	Imidazotriazini in imidazopirimidini kot inhibitorji kinaz

Country Status (37)

Country	Link
US (7)	US7767675B2 (sl)
EP (4)	EP2099447B1 (sl)
JP (1)	JP5572388B2 (sl)
KR (2)	KR101588583B1 (sl)
CN (2)	CN103288833B (sl)
AR (1)	AR066142A1 (sl)
AU (1)	AU2007323725B2 (sl)
BR (1)	BRPI0719333A2 (sl)
CA (1)	CA2669991C (sl)
CL (1)	CL2007003341A1 (sl)
CO (1)	CO6210810A2 (sl)
CR (1)	CR10841A (sl)
CY (4)	CY1116763T1 (sl)
DK (3)	DK3034075T3 (sl)
EA (2)	EA026126B1 (sl)
EC (1)	ECSP099400A (sl)
ES (3)	ES2560435T3 (sl)
FR (1)	FR22C1060I2 (sl)
GE (1)	GEP20125658B (sl)
HK (3)	HK1175700A1 (sl)
HR (3)	HRP20130106T1 (sl)
HU (2)	HUE026659T2 (sl)
IL (4)	IL198716A (sl)
LT (1)	LT3034075T (sl)
LU (1)	LUC00293I2 (sl)
ME (2)	ME02372B (sl)
MX (1)	MX2009005144A (sl)
MY (2)	MY188338A (sl)
NL (1)	NL301209I2 (sl)
NO (4)	NO346024B1 (sl)
NZ (1)	NZ577127A (sl)
PL (3)	PL3034075T3 (sl)
PT (3)	PT2497470E (sl)
RS (3)	RS52677B (sl)
SI (3)	SI3034075T1 (sl)
TW (1)	TWI429432B (sl)
WO (1)	WO2008064157A1 (sl)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX346183B (es)	2005-12-13	2017-03-10	Incyte Holdings Corp	Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas heteroarilo-sustituidas como inhibidores de cinasas janus.
PL2010493T3 (pl)	2006-04-12	2016-08-31	Merck Sharp & Dohme	Pirydyloamidy jako antagoniści kanałów wapniowych typu t
JP2010500365A (ja) *	2006-08-07	2010-01-07	インサイト・コーポレイション	キナーゼ阻害剤としてのトリアゾロトリアジン
DK3034075T3 (en)	2006-11-22	2018-10-22	Incyte Holdings Corp	IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASEI INHIBITORS
EP3495369B1 (en)	2007-06-13	2021-10-27	Incyte Holdings Corporation	Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US8637513B2 (en) *	2007-10-24	2014-01-28	Merck Sharp & Dohme Corp.	Heterocycle phenyl amide T-type calcium channel antagonists
BRPI0908504A2 (pt)	2008-02-28	2015-08-11	Novatis Ag	Compostos derivados de 3-metil-imidazo[1,2-b]piridazina, uso dos mesmos e composição farmacêutica
BRPI0912882A2 (pt) *	2008-05-21	2017-05-16	Incyte Corp	sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
WO2010002472A1 (en) *	2008-07-02	2010-01-07	Ambit Biosciences Corporation	Jak kinase modulating compounds and methods of use thereof
FR2933982A1 (fr) *	2008-07-18	2010-01-22	Sanofi Aventis	Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UY32049A (es) *	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
JOP20190231A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
SG172898A1 (en) *	2009-02-13	2011-08-29	Bayer Schering Pharma Ag	Fused pyrimidines
JP5775070B2 (ja)	2009-05-22	2015-09-09	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
PT2432472T (pt)	2009-05-22	2019-12-09	Incyte Holdings Corp	3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrilo como inibidores de jak
MX2011013816A (es)	2009-06-29	2012-04-11	Incyte Corp	Pirimidinonas como inhibidores de pi3k.
MX2012001838A (es)	2009-08-12	2012-02-29	Novartis Ag	Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CA2771432A1 (en)	2009-08-20	2011-02-24	Novartis Ag	Heterocyclic oxime compounds
US9249145B2 (en)	2009-09-01	2016-02-02	Incyte Holdings Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
KR101905350B1 (ko)	2009-12-31	2018-11-30	허치슨 메디파르마 리미티드	특정 트리아졸로피리딘 및 트리아졸로피라진, 이들의 조성물 및 이들의 사용 방법
JP5714030B2 (ja)	2010-02-03	2015-05-07	インサイトコーポレーションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
SI3354652T1 (sl)	2010-03-10	2020-08-31	Incyte Holdings Corporation	Derivati piperidin-4-il azetidina kot inhibitorji JAK1
US8518945B2 (en) *	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8410117B2 (en) *	2010-03-26	2013-04-02	Hoffmann-La Roche Inc.	Imidazopyrimidine derivatives
KR20130094710A (ko) *	2010-04-14	2013-08-26	어레이 바이오파마 인크.	Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
US9193721B2 (en)	2010-04-14	2015-11-24	Incyte Holdings Corporation	Fused derivatives as PI3Kδ inhibitors
NZ703111A (en)	2010-05-17	2016-07-29	Incozen Therapeutics Pvt Ltd	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US20110288107A1 (en)	2010-05-21	2011-11-24	Bhavnish Parikh	Topical formulation for a jak inhibitor
CA2818545C (en)	2010-11-19	2019-04-16	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2822070C (en)	2010-12-20	2019-09-17	Incyte Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
KR20140048079A (ko)	2011-02-01	2014-04-23	교와 핫꼬 기린 가부시키가이샤	축환 복소환 유도체
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CA2839767A1 (en)	2011-06-20	2012-12-27	Incyte Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UY34305A (es)	2011-09-01	2013-04-30	Novartis Ag	Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
DK2751109T3 (en)	2011-09-02	2017-01-23	Incyte Holdings Corp	HETEROCYCLYLAMINES AS PI3K INHIBITORS
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
AU2012310168B2 (en)	2011-09-15	2015-07-16	Novartis Ag	6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN103030654A (zh) *	2011-10-09	2013-04-10	济南赛文医药技术有限公司	一种小分子c-Met蛋白激酶抑制剂
JP2014528475A (ja) *	2011-10-12	2014-10-27	アレイバイオファーマ、インコーポレイテッド	５，７置換イミダゾ［１，２−ｃ］ピリミジン
CA3131037A1 (en)	2011-11-30	2013-06-06	Emory University	Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
MX2014011987A (es)	2012-04-03	2014-11-10	Novartis Ag	Combinaciones de inhibidores de cinasa de tirosina y su uso.
RU2660354C2 (ru) *	2012-04-03	2018-07-05	Новартис Аг	Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
US9193733B2 (en)	2012-05-18	2015-11-24	Incyte Holdings Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
LT3495367T (lt)	2012-06-13	2021-02-25	Incyte Holdings Corporation	Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
CN105050623B (zh) *	2012-08-16	2018-06-12	诺华股份有限公司	Pi3k抑制剂和c-met抑制剂的组合
TW201922255A (zh)	2012-11-15	2019-06-16	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
KR102366356B1 (ko)	2013-03-06	2022-02-23	인사이트 홀딩스 코포레이션	Jak 저해제를 제조하기 위한 방법 및 중간생성물
CN107312009B (zh) *	2013-04-17	2022-09-20	上海医药集团股份有限公司	喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
KR20220103810A (ko)	2013-08-07	2022-07-22	인사이트 코포레이션	Jak1 억제제용 지속 방출 복용 형태
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
GB201321732D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
GB201321736D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
AU2015217073B2 (en)	2014-02-13	2019-08-22	Incyte Holdings Corporation	Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en)	2014-02-13	2016-11-15	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
ME03580B (me)	2014-02-13	2020-07-20	Incyte Corp	Ciklopropilamini kao lsd1 inhibitori
UY36032A (es)	2014-03-14	2015-10-30	Novartis Ag	Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
BR112016022056B1 (pt)	2014-03-26	2023-04-11	Astex Therapeutics Limited	Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007736A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyrazines as lsd1 inhibitors
CN106714784A (zh) *	2014-07-25	2017-05-24	诺华股份有限公司	2‑氟‑N‑甲基‑4‑[7‑(喹啉‑6‑基甲基)咪唑并[1,2‑b][1,2,4]三嗪‑2‑基]苯甲酰胺的片剂制剂
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
RU2695230C2 (ru) *	2014-07-31	2019-07-22	Новартис Аг	Сочетанная терапия
WO2016040892A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies
WO2016054555A2 (en)	2014-10-03	2016-04-07	Novartis Ag	Combination therapies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh)	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
SG10201913036RA (en) *	2015-02-20	2020-02-27	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
TWI713497B (zh) *	2015-02-26	2020-12-21	南韓商愛思開生物製藥股份有限公司	咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
RS63963B1 (sr)	2015-02-27	2023-03-31	Incyte Holdings Corp	Postupak pripreme pi3k inhibitora
US10449211B2 (en)	2015-03-10	2019-10-22	Aduro Biotech, Inc.	Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
EP3277689B1 (en)	2015-04-03	2019-09-04	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
JP6801159B2 (ja)	2015-04-21	2020-12-16	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	イミダゾイソインドール誘導体、その製造方法及びその医薬用途
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
AU2016267872B2 (en)	2015-05-22	2019-01-17	Chong Kun Dang Pharmaceutical Corp.	Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh)	2015-07-29	2022-04-05	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
PL3317301T3 (pl)	2015-07-29	2021-11-15	Novartis Ag	Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
PE20181175A1 (es)	2015-08-12	2018-07-20	Incyte Corp	Sales de un inhibidor de lsd1
JP2019503349A (ja)	2015-12-17	2019-02-07	ノバルティスアーゲー	Ｐｄ−１に対する抗体分子およびその使用
JP2019502695A (ja)	2015-12-17	2019-01-31	ノバルティスアーゲー	ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
MX2018009252A (es)	2016-01-27	2019-01-21	Univ Zuerich	Uso de moduladores de receptores de gabaa para el tratamiento de picor.
UA123785C2 (uk) *	2016-03-28	2021-06-02	Інсайт Корпорейшн	Сполуки піролотриазину як інгібітори tam
AU2017252328B2 (en)	2016-04-22	2023-02-23	Incyte Corporation	Formulations of an LSD1 inhibitor
JP7027343B2 (ja) *	2016-05-23	2022-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｄｋ８／ｃｄｋ１９阻害剤としての新しいフェニルピラゾリルアセトアミド化合物及び誘導体
EP3507367A4 (en)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106496000A (zh) *	2016-10-19	2017-03-15	蚌埠学院	一种3‑氟‑4‑溴‑苯乙酮的合成方法
CN110382508B (zh)	2016-12-22	2022-08-02	卡里塞拉生物科学股份公司	用于抑制精氨酸酶活性的组合物和方法
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CA3066774A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
WO2019099564A1 (en)	2017-11-14	2019-05-23	Children's Medical Center Corporation	Novel imidazopyrimidine compounds and uses thereof
KR20200088398A (ko)	2017-11-14	2020-07-22	칠드런'즈 메디컬 센터 코포레이션	인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
MX2020004756A (es)	2017-11-16	2020-08-20	Novartis Ag	Terapias de combinacion.
TW201924683A (zh)	2017-12-08	2019-07-01	美商英塞特公司	用於治療骨髓增生性贅瘤的低劑量組合療法
EP3746429B1 (en)	2018-01-30	2022-03-09	Incyte Corporation	Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2022012285A (es)	2018-03-30	2023-08-15	Incyte Corp	Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
EP3788046A1 (en)	2018-05-04	2021-03-10	Incyte Corporation	Salts of an fgfr inhibitor
CN110526916B (zh) *	2018-05-23	2021-07-13	海创药业股份有限公司	氘代Capmatinib化合物及其用途
TW202015726A (zh)	2018-05-30	2020-05-01	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
CN108530337B (zh) *	2018-06-25	2020-11-03	南华大学	一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
CA3118093A1 (en) *	2018-09-28	2020-04-02	Arizona Board Of Regents On Behalf Of The University Of Arizona	Small molecule inhibitors of dyrk1/clk and uses thereof
KR20210106437A (ko)	2018-12-20	2021-08-30	노파르티스 아게	3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
AU2019401649A1 (en) *	2018-12-20	2021-07-08	Incyte Corporation	Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
EP3903828A4 (en)	2018-12-21	2022-10-05	Daiichi Sankyo Company, Limited	COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
US20220144798A1 (en)	2019-02-15	2022-05-12	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7483732B2 (ja)	2019-02-15	2024-05-15	ノバルティスアーゲー	３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4077389A1 (en)	2019-12-20	2022-10-26	Novartis AG	Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021173476A1 (en) *	2020-02-24	2021-09-02	The Trustees Of Columbia University In The City Of New York	Compounds, pharmaceutical formulations, and methods for treatment of cancer
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
CN111825678A (zh) *	2020-06-05	2020-10-27	连庆泉	一种卡马替尼的制备方法
BR112022026202A2 (pt)	2020-06-23	2023-01-17	Novartis Ag	Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2022007752A1 (zh) *	2020-07-06	2022-01-13	苏州晶云药物科技股份有限公司	苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3215903A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
EP4395769A1 (en)	2021-09-01	2024-07-10	Novartis AG	Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN113896732B (zh) *	2021-10-13	2023-09-12	沈阳红旗制药有限公司	抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) *	2022-06-22	2023-12-28	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
TW202421146A (zh)	2022-07-08	2024-06-01	瑞典商阿斯特捷利康公司	用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合
CN116903627B (zh) *	2023-05-15	2024-01-16	云白药征武科技(上海)有限公司	一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1411859A (en)	1920-12-08	1922-04-04	Marchand Robert	Process for preparing hydrate of terpin
US2837520A (en) *	1955-05-26	1958-06-03	Ind Chimica Profarmaco S R L	Fluorescent materials on the basis of tetrazoindenes
US4209621A (en) *	1979-04-27	1980-06-24	American Cyanamid Company	(Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) *	1981-09-02	1983-09-20	Diamond Shamrock Corporation	Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de)	1983-03-31	1984-10-04	Hoechst Ag, 6230 Frankfurt	Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
JPS6337347A (ja)	1986-08-01	1988-02-18	Fuji Photo Film Co Ltd	直接ポジカラ−画像形成方法
JPS63199347A (ja)	1987-02-14	1988-08-17	Konica Corp	鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja)	1987-06-12	1988-12-19	Yoshitomi Pharmaceut Ind Ltd	縮合ピリダジン化合物
US5236917A (en) *	1989-05-04	1993-08-17	Sterling Winthrop Inc.	Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja)	1989-06-12	1991-01-22	Konica Corp	ハロゲン化銀写真感光材料
IL96432A0 (en)	1989-11-30	1991-08-16	Schering Ag	Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja)	1990-02-15	1997-10-15	富士写真フイルム株式会社	ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr)	1990-05-16	1991-11-22	Lipha	Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja)	1991-01-09	1992-09-07	Konica Corp	ハロゲン化銀写真感光材料
FR2671551B1 (fr) *	1991-01-15	1993-03-12	Adir	Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5232618A (en)	1991-09-30	1993-08-03	E. I. Du Pont De Nemours And Company	Substantially constant boiling compositions of difluoromethane and trifluoroethane or perfluoroethane
JPH05232618A (ja)	1992-02-21	1993-09-10	Konica Corp	ハロゲン化銀写真感光材料
DE4309285A1 (de)	1993-03-23	1994-09-29	Boehringer Ingelheim Kg	Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
HRP980375A2 (en)	1997-07-03	1999-04-30	Argyrios Georgios Arvanitis	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
ES2137113B1 (es)	1997-07-29	2000-09-16	Almirall Prodesfarma Sa	Nuevos derivados de triazolo-piridazinas heterociclicos.
DE19734311A1 (de)	1997-08-08	1999-02-11	Bosch Gmbh Robert	Anordnung zur Übertragung optischer Signale mit Ersatzschaltungswirkung
JP4251243B2 (ja)	1998-11-26	2009-04-08	株式会社日立メディコ	領域拡張装置
JP4025468B2 (ja) *	1999-07-29	2007-12-19	三井化学株式会社	有機電界発光素子
DE60018037T2 (de)	1999-11-10	2006-01-12	Ortho-Mcneil Pharmaceutical, Inc.	Substituierte 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidine und ihren verwandten arzneimittel und verfahren
US6511987B1 (en)	1999-11-12	2003-01-28	Neurogen Corporation	Bicyclic and tricyclic heteroaromatic compounds
DE10010067A1 (de) *	2000-03-02	2001-09-06	Bayer Ag	Neue Imidazotriazinone und ihre Verwendung
AU2000240570A1 (en) *	2000-03-29	2001-10-08	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6936608B2 (en)	2000-11-10	2005-08-30	Merck Sharp & Dohme Ltd.	Imidazo-triazine derivatives as ligands for GABA receptors
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
CN1496366A (zh)	2001-03-09	2004-05-12	�Ʒ�	作为抗炎剂的三唑并吡啶
GB0107751D0 (en)	2001-03-28	2001-05-16	Pfizer Ltd	Pharmaceutically active compounds
US20050090498A1 (en)	2001-05-24	2005-04-28	Kiyohiro Samizu	3-Quinolin-2(1h)-ylideneindolin-2-one derivative
DE10130167A1 (de) *	2001-06-22	2003-01-02	Bayer Ag	Imidazotriazine
CN1281606C (zh) *	2002-03-01	2006-10-25	安斯泰来制药有限公司	含氮杂环化合物
WO2003080621A1 (en)	2002-03-19	2003-10-02	Merck & Co., Inc.	Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en)	2002-04-18	2004-09-14	Hoffmann-La Roche Inc.	2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210124D0 (en) *	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
GB0210127D0 (en) *	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
DE10230605A1 (de)	2002-07-08	2004-01-29	Bayer Ag	Substituierte Imidazotriazine
DE10230604A1 (de)	2002-07-08	2004-01-29	Bayer Ag	Heterocyclisch substituierte Imidazotriazine
JP2006508914A (ja)	2002-08-30	2006-03-16	ファイザー・プロダクツ・インク	トリアゾロ−ピリジン製造のための新規な方法および中間体
US6784297B2 (en)	2002-09-04	2004-08-31	Kopran Limited	Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
RU2005122484A (ru)	2002-12-18	2006-01-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Композиции, используемые в качестве ингибиторов протеинкиназ
UA80171C2 (en) *	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
GB0303910D0 (en) *	2003-02-20	2003-03-26	Merck Sharp & Dohme	Therapeutic agents
JP4695588B2 (ja)	2003-02-26	2011-06-08	スージェン，インク．	プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物
PA8595001A1 (es)	2003-03-04	2004-09-28	Pfizer Prod Inc	Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1640010A1 (en)	2003-07-01	2006-03-29	Astellas Pharma Inc.	Agent inducing increase in bone mass
US20060009493A1 (en)	2003-07-02	2006-01-12	Sugen, Inc.	Indolinone hydrazides as c-Met inhibitors
US7037909B2 (en)	2003-07-02	2006-05-02	Sugen, Inc.	Tetracyclic compounds as c-Met inhibitors
MXPA06000091A (es)	2003-07-02	2006-04-07	Sugen Inc	Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
US7122548B2 (en)	2003-07-02	2006-10-17	Sugen, Inc.	Triazolotriazine compounds and uses thereof
BRPI0412636A (pt)	2003-07-30	2006-09-26	S A L V A T Lab Sa	imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
TWI339206B (en)	2003-09-04	2011-03-21	Vertex Pharma	Compositions useful as inhibitors of protein kinases
WO2005040345A2 (en)	2003-09-24	2005-05-06	Vertex Pharmceuticals Incorporated	4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
ES2651730T3 (es)	2003-09-26	2018-01-29	Exelixis, Inc.	Moduladores c-Met y métodos de uso
US7144889B2 (en)	2003-10-16	2006-12-05	Hoffman-La Roche Inc.	Triarylimidazoles
US7169781B2 (en)	2003-10-17	2007-01-30	Hoffmann-La Roche Inc.	Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en)	2003-10-27	2003-12-03	Novartis Ag	Organic compounds
EP1711495A2 (en)	2004-01-23	2006-10-18	Amgen Inc.	Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
AU2005206571B8 (en)	2004-01-23	2010-09-02	Amgen Inc.	Compounds and methods of use
CN1922183B (zh)	2004-02-18	2010-05-26	万有制药株式会社	含氮的稠合杂芳环衍生物
ES2328833T3 (es) *	2004-04-02	2009-11-18	Osi Pharmaceuticals, Inc.	Inhibidores de proteina quinasa heterobiciclicos con anillo 6,6-biciclico.
US20050277650A1 (en)	2004-04-20	2005-12-15	Sundaram Venkataraman	Process for preparing aripirazole hydrate
JP5097539B2 (ja)	2004-05-07	2012-12-12	アムジエン・インコーポレーテツド	タンパク質キナーゼ調節剤および使用方法
WO2005121125A1 (en)	2004-06-09	2005-12-22	Pfizer Inc.	Ether-linked heteroaryl compounds
EP1773826A4 (en)	2004-07-02	2009-06-03	Exelixis Inc	MODULATORS OF C-MET AND THEIR METHOD OF USE
MY139689A (en) *	2004-07-20	2009-10-30	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
WO2006015123A1 (en) *	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
AU2005276135B2 (en)	2004-08-26	2011-04-28	Pfizer Inc.	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
AU2005295734A1 (en)	2004-10-15	2006-04-27	Biogen Idec Ma Inc.	Methods of treating vascular injuries
EP1813613B1 (en) *	2004-11-08	2012-12-19	Msd K.K.	Novel fused imidazole derivative
US7456289B2 (en)	2004-12-31	2008-11-25	National Health Research Institutes	Anti-tumor compounds
EP1841504B1 (en)	2005-01-13	2014-11-19	Bristol-Myers Squibb Company	Substituted biaryl compounds as factor xia inhibitors
US20090156617A1 (en)	2005-05-12	2009-06-18	Northrup Alan B	Tyrosine kinase inhibitors
EP1904501A2 (en)	2005-07-11	2008-04-02	Smithkline Beecham Corporation	Chemical compounds
WO2007015866A2 (en) *	2005-07-20	2007-02-08	Kalypsys, Inc.	Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007013673A1 (en)	2005-07-29	2007-02-01	Astellas Pharma Inc.	Fused heterocycles as lck inhibitors
WO2007025090A2 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
MX2008007049A (es)	2005-11-30	2008-10-23	Vertex Pharma	Inhibidores de c-met y usos de los mismos.
MX2008008277A (es)	2005-12-21	2009-03-04	Janssen Pharmaceutica Nv	Triazolopiridazinas como moduladores de tirosina cinasa.
CN103044432B (zh)	2005-12-23	2016-08-03	阿里亚德医药股份有限公司	双环杂芳基化合物
WO2007096764A2 (en)	2006-02-27	2007-08-30	Glenmark Pharmaceuticals S.A.	Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US8217177B2 (en) *	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) *	2006-07-14	2012-11-26	Amgen Inc	Compuestos triazolopiridinas como inhibidores de c-met
JP2010500365A (ja)	2006-08-07	2010-01-07	インサイト・コーポレイション	キナーゼ阻害剤としてのトリアゾロトリアジン
EP2081937B1 (en)	2006-10-23	2012-09-12	SGX Pharmaceuticals, Inc.	Triazolopyridazine protein kinase modulators
MY146474A (en)	2006-11-06	2012-08-15	Supergen Inc	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
DK3034075T3 (en)	2006-11-22	2018-10-22	Incyte Holdings Corp	IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASEI INHIBITORS
US20090156594A1 (en)	2007-05-21	2009-06-18	Sgx Pharmaceuticals, Inc.	Heterocyclic kinase modulators
BRPI0912882A2 (pt)	2008-05-21	2017-05-16	Incyte Corp	sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
JP5714030B2 (ja)	2010-02-03	2015-05-07	インサイトコーポレーションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
US8901323B2 (en)	2011-05-06	2014-12-02	Takasago International Corporation	Ruthenium-diamine complex and method for producing optically active compound

2007
- 2007-11-19 DK DK15191241.7T patent/DK3034075T3/en active
- 2007-11-19 NO NO20200077A patent/NO346024B1/no unknown
- 2007-11-19 MY MYPI2013000862A patent/MY188338A/en unknown
- 2007-11-19 EP EP07864592A patent/EP2099447B1/en active Active
- 2007-11-19 RS RS20130041A patent/RS52677B/en unknown
- 2007-11-19 US US11/942,130 patent/US7767675B2/en active Active
- 2007-11-19 EA EA200970501A patent/EA026126B1/ru unknown
- 2007-11-19 PL PL15191241T patent/PL3034075T3/pl unknown
- 2007-11-19 SI SI200732055T patent/SI3034075T1/sl unknown
- 2007-11-19 EA EA201691862A patent/EA032254B1/ru active IP Right Revival
- 2007-11-19 CN CN201310141352.4A patent/CN103288833B/zh active Active
- 2007-11-19 SI SI200731739T patent/SI2497470T1/sl unknown
- 2007-11-19 PT PT121587158T patent/PT2497470E/pt unknown
- 2007-11-19 ES ES12158715.8T patent/ES2560435T3/es active Active
- 2007-11-19 PT PT78645926T patent/PT2099447E/pt unknown
- 2007-11-19 NZ NZ577127A patent/NZ577127A/en unknown
- 2007-11-19 PL PL07864592T patent/PL2099447T3/pl unknown
- 2007-11-19 KR KR1020147033803A patent/KR101588583B1/ko active IP Right Grant
- 2007-11-19 KR KR1020097013022A patent/KR101532256B1/ko active IP Right Grant
- 2007-11-19 MX MX2009005144A patent/MX2009005144A/es active IP Right Grant
- 2007-11-19 ES ES15191241.7T patent/ES2689444T3/es active Active
- 2007-11-19 WO PCT/US2007/085100 patent/WO2008064157A1/en active Application Filing
- 2007-11-19 RS RS20181200A patent/RS57741B1/sr unknown
- 2007-11-19 EP EP18182215.6A patent/EP3443958A1/en active Pending
- 2007-11-19 ME MEP-2016-13A patent/ME02372B/me unknown
- 2007-11-19 ES ES07864592T patent/ES2398843T3/es active Active
- 2007-11-19 ME MEP-2013-35A patent/ME01507B/me unknown
- 2007-11-19 AU AU2007323725A patent/AU2007323725B2/en active Active
- 2007-11-19 EP EP12158715.8A patent/EP2497470B8/en active Active
- 2007-11-19 LT LTEP15191241.7T patent/LT3034075T/lt unknown
- 2007-11-19 RS RS20160017A patent/RS54510B1/en unknown
- 2007-11-19 GE GEAP200711325A patent/GEP20125658B/en unknown
- 2007-11-19 EP EP15191241.7A patent/EP3034075B1/en active Active
- 2007-11-19 PT PT15191241T patent/PT3034075T/pt unknown
- 2007-11-19 PL PL12158715T patent/PL2497470T3/pl unknown
- 2007-11-19 CA CA2669991A patent/CA2669991C/en active Active
- 2007-11-19 DK DK07864592.6T patent/DK2099447T3/da active
- 2007-11-19 MY MYPI20092064A patent/MY188335A/en unknown
- 2007-11-19 CN CN2007800503102A patent/CN101641093B/zh active Active
- 2007-11-19 BR BRPI0719333-5A patent/BRPI0719333A2/pt not_active Application Discontinuation
- 2007-11-19 DK DK12158715.8T patent/DK2497470T3/en active
- 2007-11-19 HU HUE12158715A patent/HUE026659T2/en unknown
- 2007-11-19 SI SI200731149T patent/SI2099447T1/sl unknown
- 2007-11-19 JP JP2009538473A patent/JP5572388B2/ja active Active
- 2007-11-21 AR ARP070105176A patent/AR066142A1/es active IP Right Grant
- 2007-11-22 CL CL200703341A patent/CL2007003341A1/es unknown
- 2007-11-22 TW TW096144319A patent/TWI429432B/zh active
2009
- 2009-05-12 IL IL198716A patent/IL198716A/en active IP Right Grant
- 2009-05-18 NO NO20091924A patent/NO344399B1/no active Protection Beyond IP Right Term
- 2009-06-08 CR CR10841A patent/CR10841A/es unknown
- 2009-06-10 CO CO09060491A patent/CO6210810A2/es active IP Right Grant
- 2009-06-11 EC EC2009009400A patent/ECSP099400A/es unknown
2010
- 2010-02-25 HK HK13102854.6A patent/HK1175700A1/zh unknown
- 2010-02-25 HK HK10101978.2A patent/HK1136489A1/xx unknown
- 2010-06-10 US US12/813,148 patent/US8461330B2/en active Active
2013
- 2013-02-04 CY CY20131100098T patent/CY1116763T1/el unknown
- 2013-02-07 HR HRP20130106TT patent/HRP20130106T1/hr unknown
- 2013-05-16 US US13/895,799 patent/US20130324515A1/en not_active Abandoned
2016
- 2016-01-12 CY CY20161100026T patent/CY1117108T1/el unknown
- 2016-01-25 HR HRP20160077TT patent/HRP20160077T1/hr unknown
- 2016-02-05 US US15/016,841 patent/US9944645B2/en active Active
- 2016-02-23 IL IL244244A patent/IL244244B/en active IP Right Grant
- 2016-12-16 HK HK16114386A patent/HK1225978B/zh unknown
2018
- 2018-03-20 US US15/925,996 patent/US10738052B2/en active Active
- 2018-10-05 HR HRP20181622TT patent/HRP20181622T1/hr unknown
- 2018-10-22 CY CY20181101082T patent/CY1121021T1/el unknown
2019
- 2019-06-07 NO NO20190709A patent/NO344864B1/no unknown
2020
- 2020-06-23 US US16/909,686 patent/US11261191B2/en active Active
- 2020-08-25 IL IL276928A patent/IL276928B/en unknown
2021
- 2021-07-15 IL IL284889A patent/IL284889B2/en unknown
2022
- 2022-01-13 US US17/575,371 patent/US12084449B2/en active Active
- 2022-12-12 LU LU00293C patent/LUC00293I2/en unknown
- 2022-12-13 NO NO2022057C patent/NO2022057I1/no unknown
- 2022-12-14 HU HUS2200052C patent/HUS2200052I1/hu unknown
- 2022-12-15 FR FR22C1060C patent/FR22C1060I2/fr active Active
- 2022-12-16 CY CY2022037C patent/CY2022037I2/el unknown
- 2022-12-16 NL NL301209C patent/NL301209I2/nl unknown

Also Published As

Publication number	Publication date
EP3443958A1 (en)	2019-02-20
CA2669991C (en)	2016-01-26
PT3034075T (pt)	2018-11-05
FR22C1060I1 (fr)	2023-02-03
US20200317680A1 (en)	2020-10-08
RS54510B1 (en)	2016-06-30
US20160326178A1 (en)	2016-11-10
CN103288833B (zh)	2018-01-12
TW200835481A (en)	2008-09-01
MY188338A (en)	2021-11-30
US12084449B2 (en)	2024-09-10
NO346024B1 (no)	2022-01-03
NO344399B1 (no)	2019-11-25
EA201691862A3 (ru)	2017-12-29
EP2497470B1 (en)	2015-10-28
IL276928B (en)	2022-03-01
EP2099447A1 (en)	2009-09-16
FR22C1060I2 (fr)	2023-11-17
KR20150014476A (ko)	2015-02-06
LT3034075T (lt)	2018-11-26
CN101641093B (zh)	2013-05-29
US20230002392A1 (en)	2023-01-05
JP2010510319A (ja)	2010-04-02
PT2497470E (pt)	2016-02-22
EA200970501A1 (ru)	2009-12-30
GEP20125658B (en)	2012-10-10
US8461330B2 (en)	2013-06-11
NO344864B1 (no)	2020-06-02
CY1121021T1 (el)	2020-05-29
HRP20160077T1 (hr)	2016-02-12
IL284889B1 (en)	2023-01-01
ME01507B (me)	2014-04-20
EA026126B1 (ru)	2017-03-31
KR20090094299A (ko)	2009-09-04
ES2560435T3 (es)	2016-02-19
AU2007323725A1 (en)	2008-05-29
NO20091924L (no)	2009-07-28
HRP20130106T1 (hr)	2013-03-31
US11261191B2 (en)	2022-03-01
LUC00293I2 (sl)	2024-10-04
ES2689444T3 (es)	2018-11-14
HRP20181622T1 (hr)	2018-12-14
EP2497470B8 (en)	2015-12-02
IL198716A0 (en)	2010-02-17
EP2099447B1 (en)	2012-11-07
WO2008064157A1 (en)	2008-05-29
NO2022057I1 (no)	2022-12-13
IL244244A0 (en)	2016-04-21
MX2009005144A (es)	2009-05-27
AU2007323725B2 (en)	2014-02-20
PL3034075T3 (pl)	2019-03-29
US9944645B2 (en)	2018-04-17
PT2099447E (pt)	2013-02-27
CY2022037I1 (el)	2023-01-27
PL2497470T3 (pl)	2016-04-29
ES2398843T3 (es)	2013-03-22
CY1117108T1 (el)	2017-04-05
DK2099447T3 (da)	2013-02-18
EP3034075B1 (en)	2018-07-25
CO6210810A2 (es)	2010-10-20
US10738052B2 (en)	2020-08-11
HUE026659T2 (en)	2016-07-28
CR10841A (es)	2009-06-30
EP3034075A1 (en)	2016-06-22
CN103288833A (zh)	2013-09-11
AR066142A1 (es)	2009-07-29
IL276928A (en)	2020-10-29
HK1175700A1 (zh)	2013-07-12
NL301209I1 (nl)	2022-12-21
HUS2200052I1 (hu)	2023-01-28
KR101532256B1 (ko)	2015-06-29
NO20190709A1 (no)	2009-07-28
MY188335A (en)	2021-11-30
IL198716A (en)	2016-03-31
JP5572388B2 (ja)	2014-08-13
US20080167287A1 (en)	2008-07-10
ME02372B (me)	2016-06-20
CY1116763T1 (el)	2017-03-15
IL284889B2 (en)	2023-05-01
NL301209I2 (nl)	2023-01-24
US7767675B2 (en)	2010-08-03
BRPI0719333A2 (pt)	2014-02-04
ECSP099400A (es)	2009-07-31
DK3034075T3 (en)	2018-10-22
IL244244B (en)	2020-09-30
CN101641093A (zh)	2010-02-03
NZ577127A (en)	2012-03-30
CA2669991A1 (en)	2008-05-29
RS52677B (en)	2013-06-28
EP2497470A1 (en)	2012-09-12
DK2497470T3 (en)	2015-12-07
TWI429432B (zh)	2014-03-11
CL2007003341A1 (es)	2008-04-18
EA032254B1 (ru)	2019-04-30
SI2497470T1 (sl)	2016-02-29
KR101588583B1 (ko)	2016-01-28
PL2099447T3 (pl)	2013-06-28
US20180282340A1 (en)	2018-10-04
CY2022037I2 (el)	2023-03-24
HK1225978B (zh)	2017-09-22
RS57741B1 (sr)	2018-12-31
NO20200077A1 (no)	2009-07-28
US20110136781A1 (en)	2011-06-09
US20130324515A1 (en)	2013-12-05
IL284889A (en)	2021-08-31
SI3034075T1 (sl)	2018-12-31
EA201691862A2 (ru)	2017-09-29
HK1136489A1 (en)	2010-07-02

Publication	Publication Date	Title
HUS2200052I1 (hu)	2023-01-28	Imidazotriazinok és imidazopirimidinek mint kinázgátlók
HK1144306A1 (zh)	2011-02-11	激酶抑制劑及其用途
ZA201004055B (en)	2012-09-26	4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ZA200901073B (en)	2009-12-30	Kinase inhibitor
IL211549A0 (en)	2011-05-31	Aminotriazolopyridines and their use as kinase inhibitors
ZA200900109B (en)	2010-03-31	Pyrrolotriazine kinase inhibitors
HK1114380A1 (en)	2008-10-31	Pyrrolopyrazoles as kinase inhibitors
EP2040546A4 (en)	2009-12-23	TYROSINE KINASE INHIBITORS
IL190078A0 (en)	2008-08-07	Kinase inhibitors
IL196337A0 (en)	2009-09-22	Tyrosine kinase inhibitors
IL212755A0 (en)	2011-07-31	Pyrazinopyrazines and derivatives as kinase inhibitors
SI1943243T1 (sl)	2011-04-29	Inhibotorji kinaz
HK1137756A1 (en)	2010-08-06	Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
IL197981A0 (en)	2009-12-24	Kinase inhibitors
GB0621719D0 (en)	2006-12-13	Ikk- serine-threonine protein kinase inhibitors
ZA200803287B (en)	2009-10-28	Kinase inhibitors
IL189985A0 (en)	2008-08-07	Kinase inhibitors